Sector: health
Conviction from: NASDAQ
52-week range: 2.748.59
Myriad Genetics develops and provides molecular diagnostic and genetic tests for hereditary cancer risk, oncology, prenatal, and mental-health applications.
3 tracked filer(s) hold this · 0 opened, 0 added, 3 trimmed in 30-JUN-2026
Aggregate 13FScore 64 — mean of 3 scored holder(s). Higher = the smart money in this name has the better track record.
Beyond 13F — activists, insiders, politicians & research
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-02-27 | Phanstiel S. Louise | director | 104,507 | $494,548 | Form 4 |
1 disclosed trade(s) by 1 filer(s).